The potential of specific GSK3β inhibitors in treating CKD is increasingly supported by preclinical findings, particularly those involving GSK3β-regulated pathways implicated in renal inflammation, fibrosis, and dysfunction. Here, GSK3B is linked to chronic kidney disease.